ImmunityBio (IBRX) Total Debt Growth (3y) (2017 - 2026)
Powered by 
Analysis
ImmunityBio (IBRX) Total Debt Growth (3y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 0.08% |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 19.52% |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 4.76% |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | -22.30% |
| 10 | ImmunityBio | 8.45 Bn | 8.09 Bn | 50.94 Mn | -4.85% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4.85% |
| Mar 31, 2026 | -16.33% |
| Dec 31, 2025 | -9.32% |
| Sep 30, 2025 | -5.64% |
| Jun 30, 2025 | -20.75% |
| Mar 31, 2025 | -21.59% |
| Dec 31, 2024 | -22.44% |
| Sep 30, 2024 | -4.27% |
| Jun 30, 2024 | -5.99% |
| Mar 31, 2024 | -19.66% |
| Dec 31, 2023 | -16.73% |
| Sep 30, 2023 | 110.65% |
| Jun 30, 2023 | 500.27% |
| Mar 31, 2023 | 831.84% |
| Dec 31, 2022 | 863.99% |
| Sep 30, 2022 | 656.85% |
| Jun 30, 2022 | 763.79% |
| Mar 31, 2022 | 637.70% |
| Dec 31, 2021 | 610.98% |
| Sep 30, 2021 | 423.44% |